Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 177,238 Shares of Kenvue Inc. $KVUE

Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 67.4% during the first quarter, Holdings Channel reports. The fund owned 440,373 shares of the company’s stock after purchasing an additional 177,238 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Kenvue were worth $7,592,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in KVUE. Elevation Point Wealth Partners LLC lifted its holdings in Kenvue by 50.8% during the 1st quarter. Elevation Point Wealth Partners LLC now owns 19,188 shares of the company’s stock worth $331,000 after purchasing an additional 6,465 shares during the last quarter. Sound Income Strategies LLC raised its holdings in shares of Kenvue by 64.0% during the 1st quarter. Sound Income Strategies LLC now owns 5,438 shares of the company’s stock worth $95,000 after buying an additional 2,122 shares in the last quarter. Essex Financial Services Inc. boosted its stake in shares of Kenvue by 4.1% in the 1st quarter. Essex Financial Services Inc. now owns 18,892 shares of the company’s stock valued at $326,000 after purchasing an additional 740 shares in the last quarter. IFM Investors Pty Ltd grew its holdings in Kenvue by 1.3% during the 1st quarter. IFM Investors Pty Ltd now owns 396,701 shares of the company’s stock worth $6,839,000 after acquiring an additional 4,999 shares during the last quarter. Finally, Impact Partnership Wealth LLC acquired a new position in Kenvue during the 1st quarter worth about $301,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.59% of the company’s stock.

Kenvue Stock Down 0.1%

Shares of NYSE KVUE opened at $19.81 on Monday. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.87. The firm has a market capitalization of $38.03 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 1.50 and a beta of 0.47. The business has a 50-day moving average of $17.86 and a 200-day moving average of $17.71.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.24 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KVUE. UBS Group lowered their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Barclays cut their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Citigroup lowered their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Finally, Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.